New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
08:54 EDTHEBHemispherx wins federal lawsuit regarding investment banking fees
Hemispherx Biopharma announced after more than a week in trial, a federal jury in Atlanta took only an hour to determine there was no merit to a brokerage firm's claim that Hemispherx owed the firm over $6M for commissions from private sales of stock in 2009. MidSouth Capital, sued Hemispherx in 2010 for commissions it claimed it was due under the terms of a 2008 contract which Hemispherx never signed. Investment bank Rodman & Renshaw sold more than $31M worth of Hemispherx stock in mid-2009. Rodman & Renshaw was promptly paid the commission it was due under the terms of its engagement agreement. MidSouth, whose brokers, Rob Rosenstein and Adam Cabibi, were terminated after they failed to secure a closing on several failed convertible debenture proposals, also demanded payment of a commission on the subsequent Rodman & Renshaw stock sale.
News For HEB From The Last 14 Days
Check below for free stories on HEB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
08:49 EDTHEBHemispherx announces Alferon LDO primate research peer-reviewed publication
Hemispherx Biopharma announced a peer-reviewed publication entitled "Protection from Pulmonary Tissue Damage Associated with Infection of Cynomolgus Macaques by Highly Pathogenic Avian Influenza Virus by Low Dose Natural Human IFN-á Administered to the Buccal Mucosa" in the current issue of Antiviral Research 2014. This publication is a collaborative project conducted at Viroclinics Biosciences BV, Rotterdam, an internationally recognized research facility for the study of influenza viruses. The biohazard laboratories are directed by Prof. Albert D. M. E. Osterhaus, an internationally known virologist specializing in the study of pandemic influenza. Highly pathogenic avian influenza A virus is endemic in wild birds in Asia and the Middle East, causing disease and transmissibility in domestic poultry. Infection of humans with H5N1 is associated with a high mortality rate due to an alveolar destructive primary viral pneumonia frequently expressed clinically as acute respiratory distress syndrome.
September 15, 2014
08:44 EDTHEBHemispherx Ampligen induces cross-reactive antibody formation
Subscribe for More Information
September 10, 2014
08:35 EDTHEBHemispherx expands Ebola collaborative research agreement with governments
Hemispherx Biopharma announced that it expanded its Collaborative Research Agreement to test Alferon, the only multi-species, natural alpha interferon, or IFN, commercially approved in the U.S. and Ampligen®, an experimental drug, to be evaluated against the deadly Ebola virus also under the DEA, or Data Exchange Agreement, Annex for Medical Preparedness and Bio-Defense Agreement between the Swiss Surgeon General and the US Department of Defense. The World Health Organization has warned that "The Ebola outbreak will affect more than 20,000 people in West Africa and might spread to more countries, indicating a clinical emergency all over the world."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use